 Imara Inc. IMRA, a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today presented interim results from its ongoing Phase 2a clinical trial of IMR-687 in adult patients with sickle cell disease SCD at the 25th European Hematology Association EHA Annual Congress. The data from this ongoing study demonstrated that IMR-687, an oral, once-a-day, potentially disease modifying treatment, was safe and well tolerated as a monotherapy and in combination with hydroxyurea HU. 